Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Lebanon, New Hampshire 03756


Purpose:

Exocrine pancreatic insufficiency (EPI) leading to maldigestion is a frequent finding in many diseases of the pancreas, such as chronic pancreatitis (CP). Steatorrhea is the most important digestive malfunction in EPI. Frequently, lipid malabsorption develops earlier than malabsorption of other nutrients. The current treatment of EPI includes enzyme supplementation with porcine pancreatic enzyme concentrate, consisting mainly of lipase, amylase and protease. The planned clinical study should contribute to confirming the clinical efficacy and safety of VIOKASE 16 tablets compared to placebo in patients with exocrine pancreatic insufficiency by means of the stool fat content test.


Study summary:

The study will include the following phases: the Screening Phase, the Wash-Out Phase, the Randomization Phase, and the Treatment Phase Screening Phase: Patients will undergo screening procedures prior to entry into the study. Wash-Out Phase: Stool collection will be performed to allow determination of the baseline Coefficient of Fat Absorption (CFA%). Randomization Phase: Patients who meet inclusion and exclusion criteria will be randomized in the study. Treatment Phase: Stool collection period will be performed to allow determination of the Coefficient of Fat Absorption* (CFA%) that will serve to assess the efficacy of VIOKASE 16 for the correction of steatorrhea.


Criteria:

Inclusion Criteria: - Patients must have the ability to provide Informed Consent. - Female patients of childbearing potential must have a negative pregnancy test at Screening, must use adequate contraception. - Patients must have a medical condition compatible with EPI. - Patients with Chronic Pancreatitis due to alcohol abuse may be included provided they show no clinical symptoms of recent alcohol consumption and no alcohol withdrawal symptoms. - Patients with Chronic Pancreatitis. - Patients must have evidence of EPI as demonstrated by a fecal Elastase determination. - Patients must have evidence of EPI as manifested by a Coefficient of Fat Absorption (CFA%). Exclusion Criteria: - Patients with a known hypersensitivity and/or contraindication to any of the study medications, to their excipients or to their components. - Patients with acute pancreatitis or with an acute exacerbation of Chronic Pancreatitis. - Patients with any active or recurrent malignant pancreatic tumor. - Patients with a history of significant bowel resection. - Patients with a dysmotility disorder. - Patients with insufficient body mass (i.e. Body Mass Index < 18). - Patients known to have a significant medical and/or mental disease that would compromise the patient's welfare or confound the study results. - Patients with a history of fibrosing colonopathy, cirrhosis of the liver, or portal hypertension. - Patients with a known allergy to the FD&C Blue No. 2 dye marker. - Patients who have a condition known to increase fecal fat loss. - Female patients who are pregnant or breastfeeding. - Patients who have received an Investigational drug within 30 days prior to entering the screening phase of the study. - Causes for EPI other than Chronic Pancreatitis and partial/total pancreas resection. - Patients with a history or clinical evidence of any relevant cardio- or cerebrovascular, renal, endocrine, neurologic, infectious, other gastrointestinal, hematological, oncological or psychiatric disease or emotional problems.


NCT ID:

NCT00559364


Primary Contact:

Principal Investigator
Phillip P. Toskes, MD
University of Florida


Backup Contact:

N/A


Location Contact:

Lebanon, New Hampshire 03756
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.